Biomarkers Define Probability of Receiving Second-Line Targeted Therapy in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Biomarkers Defining Probability of Receiving Second-Line Targeted Therapy in Metastatic Renal Cell Carcinoma
Med. Oncol. 2018 May 08;35(6)91, P Chrom, M Kawecki, R Stec, L Bodnar, C Szczylik, AM CzarneckaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.